Clinical Trials Browser

OTHER × Interventional × dacomitinib × Clear all

NCT03810807 2025-12-23

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT04504071 2025-09-08

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Phase 2 Active not recruiting

Non-small Cell Lung Cancer Metastatic

NCT02039336 2025-07-08

M13DAP

Phase 1/2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04027647 2025-06-12

Phase 2 Study of Dacomitinib in NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04946968 2025-06-11

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers

Phase 2 Active not recruiting

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT03755102 2025-05-15

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Phase EARLY_PHASE1 Completed

Lung Neoplasms

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Recruiting

Rare Tumor

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05271916 2023-04-19

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04811001 2023-02-21

CAPLAND

Phase 2 Unknown

NSCLC

NCT01520870 2021-07-06

Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.

Phase 2 Completed

49 enrolled 9 charts

Brain Neoplasms, Glioblastoma, Recurrence

NCT01728233 2021-05-14

HER-Uro01

Phase 2 Completed

Carcinoma, Squamous Cell, Penile Neoplasms

NCT04675008 2021-01-05

Central Nervous System(CNS) Efficacy of Dacomitinib

Phase 2 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04339829 2020-04-09

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01112527 2018-08-16

PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma

Phase 2 Completed

Glioblastoma

NCT02047747 2016-09-22

A Phase II Study of Dacomitinib in Progressive Brain Metastases

Phase 2 Terminated

4 enrolled 4 charts

Brain Neoplasms, Neoplasm Metastasis

NCT01152853 2015-11-20

PF299804-AGC

Phase 2 Completed

Gastrointestinal

Advanced Gastric Cancer

NCT01116843 2015-07-10

Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

Phase 1/2 Completed

Mouth Neoplasms

NCT01484847 2015-07-10

A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase NA Completed

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT01449201 2014-09-30

PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

Carcinoma, Squamous Cell, Head and Neck Neoplasms